Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q1 2022 Financial Results
WOBURN, Mass. , April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
WOBURN, Mass. , April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022 . The Company will host a conference call at 8:00 a.m., Eastern Time on April 26,
View HTML
Toggle Summary NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
WOBURN, Mass. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID").
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
WOBURN, Mass. , Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
WOBURN, Mass. , Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022 . The Company will host a conference call at 8:00 a.m., Eastern Time
View HTML
Toggle Summary NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
WOBURN, Mass. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell ® technology has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for reducing moderate to severe symptoms of chemotherapy induced peripheral
View HTML
Toggle Summary NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
WOBURN, Mass. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Brandi Damkier as Vice President, Clinical Partnerships. Ms. Damkier will be responsible for expanding the Company's DPNCheck ® clinical partnerships and advancing the Company's
View HTML
Toggle Summary NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
WOBURN, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022 . Dr.
View HTML
Toggle Summary NeuroMetrix Reports Q3 2021 Financial Results
WOBURN, Mass. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021 . The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological
View HTML
Toggle Summary NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
WOBURN, Mass. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care . Ms. Bell will be responsible for growing the Company's DPNCheck ® business with a primary focus on
View HTML